■含有多种活性成分,白花蛇舌草(H.diffusa)可以治疗多种肿瘤。我们研究的目的是基于现实世界的数据和实验水平,双重证明白花蛇舌草治疗肺腺癌(LUAD)的疗效和可能的分子机制。
■从SymMap数据库中提取表型-基因型和草药-靶标关联。从MalaCards数据库中提取疾病基因关联。进一步对与中医相关的基因收集和与疾病和症状相关的基因收集进行了基于分子网络的相关性分析。然后,网络分离SAB指标用于评估中医与症状之间的网络接近关系.最后,细胞凋亡实验,蛋白质印迹,和Real-timePCR用于生物实验水平验证分析。
■研究中包括85,437份电子病历(318例LUAD患者)。LUAD组含有白花蛇舌草的处方比例远高于非LUAD组(p<0.005)。我们统计了该组和未使用白花蛇舌草的患者的症状缓解情况:除了疲劳等症状,心悸,头晕,使用组的症状改善率高于未使用组。我们选择了使用组中最常见的五种症状,即,咳嗽,咳痰,疲劳,胸闷和喘息。我们将上述五个症状基因合并为一组。获得的重叠基因是CTNNB1、STAT3、CASP8和APC。生物学实验选择CTNNB1靶点显示,药物干预组LUADA549细胞增殖率显著低于对照组,它是浓度依赖性的。H.diffusa可促进A549细胞凋亡,高浓度药物组的细胞凋亡率明显高于低浓度药物组。药物干涉组CTNNB1基因的转录和表达程度显著下降。
■H.白花蛇抑制LUADA549细胞增殖并促进其凋亡,这可能与白花蛇舌草能调节CTNNB1的表达有关。
UNASSIGNED: With a variety of active ingredients, Hedyotis Diffusa (H. diffusa) can treat a variety of tumors. The purpose of our study is based on real-world data and experimental level, to double demonstrate the efficacy and possible molecular mechanism of H. diffusa in the treatment of lung adenocarcinom (LUAD).
UNASSIGNED: Phenotype-genotype and herbal-target associations were extracted from the SymMap database. Disease-gene associations were extracted from the MalaCards database. A molecular network-based correlation analysis was further conducted on the collection of genes associated with TCM and the collection of genes associated with diseases and symptoms. Then, the network separation SAB metrics were applied to evaluate the network proximity relationship between TCM and symptoms. Finally, cell apoptosis experiment, Western blot, and Real-time PCR were used for biological experimental level validation analysis.
UNASSIGNED: Included in the study were 85,437 electronic medical records (318 patients with LUAD). The proportion of prescriptions containing H. diffusa in the LUAD group was much higher than that in the non-LUAD group (p < 0.005). We counted the symptom relief of patients in the group and the group without the use of H. diffusa: except for symptoms such as fatigue, palpitations, and dizziness, the improvement rate of symptoms in the user group was higher than that in the non-use group. We selected the five most frequently occurring symptoms in the use group, namely, cough, expectoration, fatigue, chest tightness and wheezing. We combined the above five symptom genes into one group. The overlapping genes obtained were CTNNB1, STAT3, CASP8, and APC. The selection of CTNNB1 target for biological experiments showed that the proliferation rate of LUAD A549 cells in the drug intervention group was significantly lower than that in the control group, and it was concentration-dependent. H. diffusa can promote the apoptosis of A549 cells, and the apoptosis rate of the high-concentration drug group is significantly higher than that of the low-concentration drug group. The transcription and expression level of CTNNB1 gene in the drug intervention group were significantly decreased.
UNASSIGNED: H. diffusa inhibits the proliferation and promotes apoptosis of LUAD A549 cells, which may be related to the fact that H. diffusa can regulate the expression of CTNNB1.